Weed (BUDZ) Other financing activities (2017 - 2018)
Weed's (BUDZ) quarterly Other financing activities came in at -$200770.0 in Q4 2018, down 769.23% year-on-year from $30000.0 in Q4 2017, and down 200.0% quarter-over-quarter from $200770.0 in Q1 2018.
Weed (BUDZ) Other financing activities (2017 - 2018) Analysis & Trends
Weed's Other financing activities history runs 2 years deep, the most recent figure standing at -$200770.0 for Q4 2018.
- On a quarterly basis, Other financing activities fell 769.23% year-over-year to -$200770.0 in Q4 2018; TTM through Sep 2019 was -$200770.0, a 187.0% decrease from a year earlier, with the FY2017 full-year figure at $30000.0, changed N/A from the prior year.
- Other financing activities eased to -$200770.0 in Q4 2018 per BUDZ's latest filing, from $200770.0 in the prior quarter.
- Across five years, Other financing activities topped out at $200770.0 in Q1 2018 and bottomed at -$200770.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Weed | 3.72 Mn | 3.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -200,770.00 |
| Dec 31, 2018 | -200,770.00 |
| Mar 31, 2018 | 200,770.00 |
| Mar 31, 2018 | 200,770.00 |
| Dec 31, 2017 | 30,000.00 |
| Dec 31, 2017 | 30,000.00 |